Latest News

Márcia Waddington-Cruz, MD, PhD  (Credit: Radcliffe Cardiology)
Eplontersen Exceeds Established Thresholds for Symptom and Disability Improvement in ATTRv-PN

May 22nd 2025

Newly presented findings from the NEURO-TTRansform study identified thresholds for meaningful improvement in symptoms and disability, which were exceeded by eplontersen treatment.

ATTRv-PN Treatment Vutrisiran Demonstrates Long-Term Efficacy in Open-Label HELIOS-A Extension
ATTRv-PN Treatment Vutrisiran Demonstrates Long-Term Efficacy in Open-Label HELIOS-A Extension

May 22nd 2025

Once-Daily Oral Pill for Obstructive Sleep Apnea Shows Promising Phase 3 Results, Paving Way for FDA Submission
Once-Daily Oral Pill for Obstructive Sleep Apnea Shows Promising Phase 3 Results, Paving Way for FDA Submission

May 22nd 2025

Gene Therapy Atidarsagene Autotemcel Improves Peripheral Neuropathy of Pre-Symptomatic Late-Infantile Metachromatic Leukodystrophy
Gene Therapy Atidarsagene Autotemcel Improves Peripheral Neuropathy of Pre-Symptomatic Late-Infantile Metachromatic Leukodystrophy

May 22nd 2025

Rajiv Mallick, PhD  (Credit: LinkedIn)
Real-World Study Highlights Reduced Disability Progression of CIDP With Immunoglobulin Therapy

May 21st 2025

Coverage of PNS 2025

Get direct access to interviews with experts, straight from the conference floor in Vienna, as well as the latest data and clinical news updates.

PNS 2025

Conference Coverage

View All
Márcia Waddington-Cruz, MD, PhD  (Credit: Radcliffe Cardiology)
Eplontersen Exceeds Established Thresholds for Symptom and Disability Improvement in ATTRv-PN

May 22nd 2025

ATTRv-PN Treatment Vutrisiran Demonstrates Long-Term Efficacy in Open-Label HELIOS-A Extension
ATTRv-PN Treatment Vutrisiran Demonstrates Long-Term Efficacy in Open-Label HELIOS-A Extension

May 22nd 2025

Mechanism and Rationale Behind Imlifidase for Guillain-Barré Syndrome: Elisabeth Sonesson, PhD
Mechanism and Rationale Behind Imlifidase for Guillain-Barré Syndrome: Elisabeth Sonesson, PhD

May 22nd 2025

Gene Therapy Atidarsagene Autotemcel Improves Peripheral Neuropathy of Pre-Symptomatic Late-Infantile Metachromatic Leukodystrophy
Gene Therapy Atidarsagene Autotemcel Improves Peripheral Neuropathy of Pre-Symptomatic Late-Infantile Metachromatic Leukodystrophy

May 22nd 2025

Video Series
Video Interviews
Podcasts

Most Recent

© 2025 MJH Life Sciences

All rights reserved.